Primary cutaneous B-cell lymphomas: Recent advances in diagnosis and management

Cancer Control

Volumn 19, Issue 3, 2012, Pages 236-244

  Sokol, Lubomir ^a   Naghashpour, Mojdeh ^a   Frank Glass, L ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CUTANEOUS B CELL LYMPHOMA; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; GENE AMPLIFICATION; GENE EXPRESSION; GENE REARRANGEMENT; HISTOLOGY; HOMOZYGOSITY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MULTIPLE CYCLE TREATMENT; PATHOGENESIS; PRIMARY CUTANEOUS DIFFUSE LARGE B CELL LYMPHOMA; PRIMARY CUTANEOUS FOLLICLE CENTER LYMPHOMA; PRIMARY CUTANEOUS MARGINAL ZONE LYMPHOMA; SKIN BIOPSY; SKIN LYMPHOMA; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84864501928     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481201900308     Document Type: Article

References (43)

1. Swerdlov SH, Campo E, Harris NL, et al. World Health Organization (WHO) Classifi cation of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: World Health Organization; 2008.
2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classifi cation for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
3. Willemze R, Kerl H, Sterry W, et al. EORTC classifi cation for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90(1):354-371.
4. Jaffe E, Harris N, Stein H, et al. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. In: World Health Organization (WHO) Classifi cation of Tumors. Lyon, France: World Health Organization;2001.
5. Kim YH, Willemze R, Pimpinelli N, et al. TNM classifi cation system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(2):479-484.
6. Mian M, Marcheselli L, Luminari S, et al. CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). Ann Hematol. 2011;90(4):401-408.
7. Smith BD, Smith GL, Cooper DL, et al. The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry. J Clin Oncol. 2005;23(15):3390-3395.
8. ®). Non-Hodgkin's Lymphomas. Version 4. 2011. http://www.NCCN.org. Accessed February 20, 2012.
9. Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008;112(5):1600-1609.
10. Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassifi cation of 300 primary cutaneous B-cell lymphomas according to the new WHOEORTC classifi cation for cutaneous lymphomas: comparison with previous classifi cations and identifi cation of prognostic markers. J Clin Oncol. 2007;25(12):1581-1587.
11. Garbe C, Stein H, Dienemann D, et al. Borrelia burgdorferi-associated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases. J Am Acad Dermatol. 1991;24(4):584-590.
12. Jelić S, Filipović-Ljesković I. Positive serology for Lyme disease borrelias in primary cutaneous B-cell lymphoma: a study in 22 patients: is it a fortuitous fi nding? Hematol Oncol. 1999;17(3):107-116.
13. Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol. 2000;24(9):1279-1285.
14. Hofbauer GF, Kessler B, Kempf W, et al. Multilesional primary cutaneous diffuse large B-cell lymphoma responsive to antibiotic treatment. Dermatology. 2001;203(2):168-170.
15. Kütting B, Bonsmann G, Metze D, et al. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol. 1997;36(2 pt 2):311-314.
16. Takino H, Li C, Hu S, et al. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathological study of cases from Asia, Germany, and the United States. Mod Pathol. 2008;21(12):1517-1526.
17. Goteri G, Ranaldi R, Simonetti O, et al. Clinicopathological features of primary cutaneous B-cell lymphomas from an academic regional hospital in central Italy: no evidence of Borrelia burgdorferi association. Leuk Lymphoma. 2007;48(11):2184-2188.
18. Schöllkopf C, Melbye M, Munksgaard L, et al. Borrelia infection and risk of non-Hodgkin lymphoma. Blood. 2008;111(12):5524-5529.
19. Dijkman R, Tensen CP, Jordanova ES, et al. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J Clin Oncol. 2006;24(2):296-305.
20. Bhagavathi S, Blenc AM, Amin M, et al. Primary cutaneous large B-cell lymphoma shows activation of nuclear factor kappa B and low incidence of Epstein-Barr virus. Am J Dermatopathol. 2010;32(5):439-441.
21. van Maldegem F, van Dijk R, Wormhoudt TA, et al. The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 infl ammatory environment. Blood. 2008;112(8):3355-3361.
22. Perez M, Pacchiarotti A, Frontani M, et al. Primary cutaneous Bcell lymphoma is associated with somatically hypermutated immunoglobulin variable genes and frequent use of VH1-69 and VH4-59 segments. Br J Dermatol. 2010;162(3):611-618.
23. Dijkman R, Tensen CP, Buettner M, et al. Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID. Blood. 2006;107(12):4926-4929.
24. Pasqualucci L, Bhagat G, Jankovic M, et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet. 2008;40(1):108-112.
25. Quereux G, Frot AS, Brocard A, et al. Routine bone marrow biopsy in the initial evaluation of primary cutaneous B-cell lymphoma does not appear justifi ed. Eur J Dermatol. 2009;19(3):216-220.
26. Senff NJ, Kluin-Nelemans HC, Willemze R. Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. Br J Haematol. 2008;142(1):52-56.
27. Fenot M, Quereux G, Brocard A, et al. Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type. Eur J Dermatol. 2010;20(6):753-757.
28. Valencak J, Weihsengruber F, Rappersberger K, et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol. 2009;20(2):326-330.
29. Morales AV, Advani R, Horwitz SM, et al. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. J Am Acad Dermatol. 2008;59(6):953-957.
30. Kyrtsonis MC, Siakantaris MP, Kalpadakis C, et al. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol. 2006;77(4):300-303.
31. Heinzerling L, Dummer R, Kempf W, et al. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol. 2000;136(3):374-378.
32. Kerl K, Prins C, Saurat JH, et al. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol. 2006;155(6):1197-1200.
33. Roguedas AM, Watier H, Paintaud G, de Muret A, Vaillant L, Machet L. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic effi cacy in primary cutaneous B-cell lymphoma. Br J Dermatol. 2005;152(3):541-544.
34. Dummer R, Eichmüller S, Gellrich S, et al. Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Mol Ther. 2010;18(6):1244-1247.
35. Maza S, Gellrich S, Assaf C, et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: fi rst results of a prospective, monocentre study. Leuk Lymphoma. 2008;49(9):1702-1709.
36. Senff NJ, Hoefnagel JJ, Neelis KJ, et al. Results of radiotherapy in 153 primary cutaneous B-cell lymphomas classifi ed according to the WHO-EORTC classifi cation. Arch Dermatol. 2007;143(12):1520-1526.
37. Neelis KJ, Schimmel EC, Vermeer MH, et al. Low-dose palliative radiotherapy for cutaneous B-and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2009;74(1):154-158.
38. Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol. 2007;143(9):1144-1150.
39. Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Arch Dermatol. 2005;141(9):1139-1145.
40. Hallermann C, Niermann C, Fischer RJ, Schulze HJ. Survival data for 299 patients with primary cutaneous lymphomas: a monocentre study. Acta Derm Venereol. 2011;91(5):521-525.
41. Gerami P, Wickless SC, Rosen S, et al. Applying the new TNM classifi cation system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome Yes. in primary cutaneous marginal zone lymphoma. J Am Acad Dermatol. 2008;59(2):245-254.
42. Koens L, Vermeer MH, Willemze R, et al. IgM expression on paraffi n sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma. Am J Surg Pathol. 2010;34(7):1043-1048.
43. Senff NJ, Zoutman WH, Vermeer MH, et al. Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol. 2009;129(5):1149-1155.